NEW YORK, April 29, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Zimmer Holdings, Inc. (NYSE: ZMH), Cesca Therapeutics Inc. (NYSE: KOOL), NuVasive, Inc. (NYSE: NUVA), Smith & Nephew plc (NYSE: SNN) and Cardiovascular Systems Inc. (NYSE: CSII). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1729-100free.
Zimmer Holdings, Inc. Analyst Notes
On April 24, 2014, Zimmer Holdings, Inc. (Zimmer) reported its Q1 2014 financial results. Net sales totaled $1.2 billion, up 2.0% YoY; adjusted net earnings totaled $258.1 million, up 7.2% YoY; adjusted diluted EPS for the quarter were $1.50, up 6.4% YoY. "As we continue focus on the execution of our quality and operational excellence initiatives, we believe that the Company is well positioned for continued growth in the evolving global healthcare landscape through the ongoing development and commercialization of innovative and clinically relevant solutions," said David Dvorak, Zimmer President and CEO. The Company expects full-year 2014 revenues to grow 3% to 5% YoY on a constant currency basis. In addition, the Company now expects full-year 2014 diluted EPS to be in a range of $4.90 to $5.10 on a reported basis and $6.00 to $6.20 on an adjusted basis with the higher average shares. The full analyst notes on Zimmer Holdings are available to download free of charge at:
Cesca Therapeutics Inc. Analyst Notes
On April 16, 2014, Cesca Therapeutics Inc. (Cesca) announced the realignment of its sales, marketing and technical support organization to further strengthen its cord blood business and clinical commercial programs. According to Cesca, the restructuring will include Hal Baker transitioning from his current role as Vice President of Commercial Operations, to an external consulting and advisory role, which will ensure an orderly and seamless transition of his existing responsibilities with specific attention given to cord blood sales and marketing initiatives. The Company also appointed Tim Lee as Director of International Sales where he will lead global cord blood product sales and services. The full analyst notes on Cesca Therapeutics are available to download free of charge at:
NuVasive, Inc. Analyst Notes
On April 14, 2014, NuVasive Inc. (NuVasive) celebrated the first anniversary of its NuVasive Japan office in Tokyo. NuVasive Japan is headed by Executive Vice President of Asia Pacific, Takaaki Tanaka and the office has been greatly successful in providing outstanding customer and patient support. Russell Powers, NuVasive Executive Vice President of International said, "We are changing spine surgery in Japan and I applaud all of the NuVasive teams who have worked tirelessly to bring our game-changing technology to Japan. It is an exceptional start to our strong future in an exciting market. We are clearly building momentum in Japan and furthering the shift towards minimally disruptive approaches globally." The full analyst notes on NuVasive are available to download free of charge at:
Smith & Nephew plc Analyst Notes
On April 11, 2014, Smith & Nephew plc (Smith & Nephew) announced that it will release its Q1 FY 2014 financial results (period ended March 29, 2014) on May 1, 2014, Thursday at 7:00 a.m. BST/2:00 a.m. EST. Following the earnings release, the Company will also hold a conference call at 8:30 a.m. BST/3:30 a.m. EST, which can be heard live via audio webcast on the Company's website. The full analyst notes on Smith & Nephew are available to download free of charge at:
Cardiovascular Systems Inc. Analyst Notes
On April 24, 2014, Cardiovascular Systems Inc. (Cardiovascular Systems) stock ended the day at $28.58 compared to the previous day's closing price at $27.32, representing a 4.61% growth. The Company's stock rose 8.83% over the past three trading days compared to the NASDAQ Composite which rose 0.65% during the same trading period. The full analyst notes on Cardiovascular are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review